Navigation Links
Sinovac to Participate in Four Investor Conferences in September 2011
Date:8/30/2011

BEIJING, Aug. 30, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that Dr. Weidong Yin, President and CEO, Ms. Nan Wang, Interim Chief Financial Officer, and Ms. Helen Yang, Investor Relations Manager, are scheduled to attend four upcoming investor conferences in New York City and Boston.

  • Rodman & Renshaw Annual Global Investment Conference, New York City
  • Sinovac is scheduled to present at 2:50 pm on Monday, September 12, 2011 and will be participating in one-on-one meetings on September 12, 2011.

  • Morgan Stanley Global Healthcare Conference, New York City
  • Sinovac is scheduled to present at 1:35 pm ET on Tuesday, September 13, 2011 and will be participating in one-on-one meetings on September 13 and 14, 2011.
  • A live webcast of the presentation will be available online on the Investor Relations Home page of the Sinovac's corporate Web site at http://www.sinovac.com.

  • Morgan Stanley China Healthcare Day Conference, Boston
  • Sinovac will be participating in one-on-one meetings on Thursday, September 15, 2011

  • UBS Global Life Sciences Conference, New York City
  • Sinovac is scheduled to present at 4:00 pm ET on Monday, September 19, 2011 and will be participating in one-on-one meetings on September 19, 2011.

  • About SinovacSinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against hand, foot & mouth disease), mumps, rubella, HIB, epidemic meningitis, varicella and human rabies. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines, which is anticipated to be launched in 2011.

    Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.Helen Yang/Chris LeeSinovac Biotech Ltd.Tel: +86-10-8279-9871/9659Fax: +86-10-6296-6910Email: ir@sinovac.com Investors:Stephanie CarringtonThe Ruth GroupTel: +1-646-536-7017Email: scarrington@theruthgroup.comMedia:Victoria AguiarThe Ruth GroupTel: +1-646-536-7013Email: vaguiar@theruthgroup.com
    '/>"/>

    SOURCE Sinovac Biotech Ltd.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Sinovac to Host Conference Call to Report First Quarter 2011 Unaudited Financial Results
    2. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2010 Audited Financial Results
    3. Sinovac Participates in Two Investor Conferences in November
    4. Sinovac to Participate at 2010 Shanghai CPhI Exhibition
    5. Sinovac to Present at 2010 UBS Global Specialty Pharmaceuticals Conference
    6. Sinovac Reports Unaudited First Quarter 2010 Financial Results
    7. Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
    8. Sinovac Announces Upsizing and Pricing of Common Share Offering
    9. Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
    10. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
    11. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/2/2016)... Dec. 2, 2016 /PRNewswire/ - bioLytical Laboratories, a world leader in rapid infectious disease ... Kenya,s Pharmaceutical Association members. (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ... ... , , ... Kenya Pharmaceutical Association (KPA) to introduce the INSTI HIV Self Test to 350 pharmacy ...
    (Date:11/30/2016)... announced the appointment of Joshua F. Coleman , M.D., ... Coleman will oversee clinical content development and curation of scientific ... suite empowers molecular pathologists with a seamless workflow for the ... quality control through reporting. ... , , Prior ...
    (Date:11/30/2016)... , Nov. 30, 2016 /PRNewswire/ - Portage Biotech Inc. ... Exchange: PBT.U), is excited to announce the formation ... on developing preclinical ophthalmology assets through proof of ... anti-inflammatory created by Portage Pharmaceuticals Limited and being ... ocular surface and anterior segment diseases. This agent ...
    (Date:11/30/2016)... 30, 2016  The Allen Institute for Cell ... first publicly available collection of gene edited, fluorescently ... key cellular structures with unprecedented clarity. Distributed through ... tools are a crucial first step toward visualizing ... what makes human cells healthy and what goes ...
    Breaking Biology Technology:
    (Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
    (Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
    (Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
    Breaking Biology News(10 mins):